Buy Crestor (Rosuvastatin) pills

Crestor (Rosuvastatin) pills

571231USD

Description

Features

Reviews

Instructions for Crestor (Rosuvastatin) pills

English product name
Crestor®

Release form
tabletop film sheath, 5 mg: 28 or 98 pcs

Description Crestor
The tablets are covered with a yellow film shell, round, double-convex, with an engraving of "ZD4522 5" on one side.

1 tab.
rozuvastatin (as calcium rozuvastatin) 5 mg
Auxiliary substances: lactose monohydrate - 93.08 mg, cellulose microcrystalline - 31.02 mg, calcium phosphate - 11.32 mg, crospovidone - 7.5 mg, magnesium stearate - 1.88 mg.

The film sheath consists of monohydrate lactose 1.8 mg, hypromellose 1.26 mg, triacetine (glycerine triacetate) 0.036 mg, dioxide titanium 0.9 mg, iron oxide yellow dye 0.18 mg.

14 pcs. - blister packs (2) - cardboard packs.
14 pcs. - blister packs (7) - cardboard packs.
14 pcs. - blister packs (2) - cardboard packs with first opening control.
14 pcs. - blister packs (7) - cardboard packs with first opening control.

ATC codes
C10AA07 Rosuvastatin

Clinical-pharmacological groups / Group affiliation
Hypolipidemic drug

Active substance
calcium rosuvastatin

Pharmacotherapy group Crestor

Hypolipidemic agent - reductase inhibitor GMG-CoA

Storage Conditions
The drug should be stored in a place inaccessible to children at a temperature not higher than 30 ° C.

Best before date
The shelf life is three years. Do not apply after the expiry date indicated on the package.

Method of use, course and dosage Crestor

Inside, do not chew or shred the pill, swallow whole, water. The drug can be prescribed at any time of the day, regardless of food intake. Before starting Crestor® therapy, the patient must follow a standard hypocholesterolemic diet and continue to follow it during treatment. The dose of the drug should be selected individually according to the objectives of the therapy and the therapeutic response to the treatment, taking into account the current recommendations for target concentrations of lipids.

The recommended initial dose for patients starting to take the drug or for patients transferred from other GMG-CoA reductase inhibitors should be 5 or 10 mg of Crestor® 1 times/day. When choosing the initial dose, the individual cholesterol concentration should be taken into account and the possible risk of cardiovascular complications should be taken into account, as well as the potential risk of side effects should be assessed. If necessary, the dose can be increased to a greater extent after 4 weeks.

Due to possible side effects at a dose of 40 mg, compared to lower doses of the drug, an increase of up to 40 mg, after an additional dose above the recommended initial dose during 4 weeks of therapy, can only be performed in patients with severe hypercholesterolemia and high risk of cardiovascular complications (especially in patients with familial hypercholesterolemia) who have not achieved the desired result of therapy at a dose of 20 mg and who will be under the supervision of a specialist. Especially careful monitoring of patients receiving the drug at a dose of 40 mg is recommended.

It is not recommended to prescribe the drug at a dose of 40 mg to patients who have not previously visited the doctor. After 2-4 weeks of therapy and/or when the dose of Crestor® is increased, lipid exchange rates should be monitored (dose correction is required if necessary).

Testimony Crestor

primary Fredrickson hypercholesterolemia (type IIa, including familial heterozygous hypercholesterolemia) or mixed
hypercholesterolemia (type IIb) as a supplement to diet when diet and other non-medicamental treatments (e.g. exercise,
reduced body weight) are inadequate;
family homozygous hypercholesterolemia as a supplement to diet and other lipidesant therapy (e.g. LDL-apheresis), or in
cases where such therapy is not effective enough;
hypertriglyceridemia (Fredrikson type IV) as a supplement to the diet;
to slow the progression of atherosclerosis as a supplement to diet in patients who are shown therapy to reduce th
concentration of total HS and HS-LDL;
primary prevention of major cardiovascular complications (stroke, heart attack, arterial revascularization) in adult
patients without clinical signs of IBS, but with an increased risk of its development (age over 50 years for men and over 60
years for women, increased concentration of C-reactive protein (≥ 2 mg/l) with at least one additional risk factor such as
arterial hypertension,
low concentration of HC-HDL,
smoking, family history of early onset IBS).

Pharmacological effect

Mechanism of action

Rozuvastatin is a selective, competitive inhibitor of GMG-CoA reductase, an enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A into mevalonic acid, a precursor to cholesterol. The main target of rozuvastatin action is the liver, where cholesterol (CS) synthesis and low-density lipoprotein (LDL) catabolism are carried out.

Rozuvastatin increases the number of hepatic LDL receptors on the cell surface, increasing LDL uptake and catabolism, which in turn leads to inhibition of very low-density lipoprotein synthesis (LDL), thereby reducing the total amount of LDL and LDL.